Objective To develop evidence-based guidelines on best available treatment options for
patients with stage IIIB non-small cell lung cancer (NSCLC). Methods A review was …

Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …

Study objectives Stage IIIA non-small cell lung cancer represents a relatively heterogeneous
group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and …

Lung cancer is the leading cause of cancer death worldwide. Majority of newly diagnosed
lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered …

Background Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable,
clinical entity in patients given the diagnosis at a time when their performance status (PS) …

PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Background Stage IV non-small cell lung cancer (NSCLC) remains a treatable but incurable
disease. Methods A MEDLINE search was performed to identify pertinent peer-reviewed …

The purpose of this article is to provide updated recommendations for the treatment of
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …

Management of stage III non-small cell lung cancer (NSCLC) is very challenging due to
being a group of widely heterogeneous diseases that require multidisciplinary approaches …

Few issues are as controversial in non-small cell lung cancer as the management of patients
with stage IIIA-N2 non-small cell lung cancer. This manuscript reviews the reasons and the …